GT 90001
Alternative Names: GT-90001; GT90001CLatest Information Update: 25 Feb 2024
At a glance
- Originator Pfizer
- Developer Alphamab Oncology; Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ACVRL1 protein antagonists; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Liver cancer
- Phase I/II Solid tumours
Most Recent Events
- 27 Sep 2022 Suzhou Kintor Pharmaceuticals completes a phase I/II trial for Liver cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (IV) (NCT03893695)
- 02 Nov 2021 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04984668)
- 02 Nov 2021 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Taiwan (IV) (NCT04984668)